OncoMatch/Clinical Trials/NCT04655118
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Is NCT04655118 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TL-895 for myelofibrosis.
Treatment: TL-895 — This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis (Cohorts 1-3) or Indolent Systemic Mastocytosis (Cohort 5). Participants must be diagnosed with Myelofibrosis and be relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive JAKi treatment, or be diagnosed with Indolent Systemic Mastocytosis.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myeloproliferative Neoplasm
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: BTK inhibitor
Prior treatment with any BTK or BMX inhibitors
Cannot have received: JAK inhibitor
Prior treatment with JAKi within 28 days prior to study treatment
Cannot have received: other targeted therapy (Avapritinib, bezuclastinib, BLU-263, elenestinib)
Prior treatment with Avapritinib, bezuclastinib, or BLU-263/elenestinib
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Adequate hematologic, hepatic, and renal functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado - Aurora Cancer Center · Aurora, Colorado
- Mayo Clinic - Rochester · Rochester, Minnesota
- Gabrail Cancer Center · Canton, Ohio
- University of Cincinnati (UC) Physicians Company, LLC · Cincinnati, Ohio
- Ohio State University · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify